Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Oligometastasis|Lung Cancer|Colo-rectal Cancer|Prostate Cancer
PROCEDURE: Stereotactic Ablative Radiotherapy|OTHER: Best Practice
Overall Survival - Trial 1 and 2, Calculated from the time of randomization until death, UP to 5 years|Androgen DeprivationTherapy (ADT)-free survival - Trial 3, The time from radomization until receipt of ADT, death due to any cause, end of study or last follow up., Up to 5 years
Change in Quality of Life, Quality of life will be assessed using The EORTC Core Quality of Life questionnaire (EORTC-QLC30). This questionnaire measures cancer patients' physical, psychological and social functions. This 30 item questionnaire ranges from 1 (not at all ) to 4 (Very much) except for the global health status/quality-of-life scale, which has response options ranging from (1) "very poor" to (7) "excellent", Up to 5 years after radiation treatment|Physician determined Radiation related toxicity, To document toxicity in patients using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 5 for each organ treated, 5 years
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers